OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
SCIB59

SciBase Holding AB (publ)

Advanced Medical Equipment & TechnologyVerified

SciBase Holding AB (publ) has a strong liquidity position, with cash and equivalents amounting to 43.27 million SEK, representing 58.6% of total assets. The company has no long-term debt, and its debt-to-equity ratio is 0.0, indicating a conservative capital structure. The current ratio of 3.71 suggests the company has sufficient short-term assets to cover its liabilities. The company's profitability metrics are negative, with a return on equity of -28.45% and a return on assets of -20.42%. These figures indicate that SciBase is currently generating losses relative to its equity and asset base. The operating income is -14.70 million SEK, and the net income is -15.05 million SEK, reflecting a challenging financial performance. SciBase's revenue is concentrated in a single business segment, as disclosed in its financial statements. There is no geographic diversification data available in the provided information, but the company's operations are primarily based in Sweden. The lack of segment and geographic diversification could pose concentration risks. Looking ahead, SciBase is expected to face continued financial pressure. Analysts estimate a mean revenue of 70 million SEK for the current fiscal year, compared to the last actual revenue of 40.46 million SEK. The mean EBIT estimate is -79 million SEK, indicating a significant operating loss. The company's free cash flow is negative at -14.39 million SEK, and capital expenditures are minimal at -127,000 SEK. The risk assessment for SciBase indicates low liquidity and dilution risks. There are no immediate filing-based liquidity or dilution flags. The company's dilution potential is low, and no significant adjustments have been applied to its valuation metrics. The absence of long-term debt and the high cash reserves contribute to the low liquidity risk. Recent events and filings do not indicate any major changes in SciBase's business strategy or financial position. The company's ESG score, particularly the social pillar, is 25.77 out of 100, suggesting room for improvement in social responsibility initiatives. Analysts have provided a uniform price target of 0.50 SEK, indicating a consensus on the stock's valuation.

30-day price · SCIB+0.10 (+26.6%)
Low$0.35High$0.47Close$0.45As of13 May, 00:00 UTC
Profile
CompanySciBase Holding AB (publ)
TickerSCIB.ST
SectorHealthcare
BusinessHealthcare Services & Equipment
Industry groupHealthcare Services & Equipment
IndustryAdvanced Medical Equipment & Technology
AI analysis

Business. SciBase Holding AB (publ) operates in the healthcare equipment industry, providing advanced medical equipment and technology solutions.

Classification. SciBase is classified under the Healthcare sector, specifically in the Advanced Medical Equipment & Technology industry, with a confidence level of 0.92.

SciBase Holding AB (publ) has a strong liquidity position, with cash and equivalents amounting to 43.27 million SEK, representing 58.6% of total assets. The company has no long-term debt, and its debt-to-equity ratio is 0.0, indicating a conservative capital structure. The current ratio of 3.71 suggests the company has sufficient short-term assets to cover its liabilities. The company's profitability metrics are negative, with a return on equity of -28.45% and a return on assets of -20.42%. These figures indicate that SciBase is currently generating losses relative to its equity and asset base. The operating income is -14.70 million SEK, and the net income is -15.05 million SEK, reflecting a challenging financial performance. SciBase's revenue is concentrated in a single business segment, as disclosed in its financial statements. There is no geographic diversification data available in the provided information, but the company's operations are primarily based in Sweden. The lack of segment and geographic diversification could pose concentration risks. Looking ahead, SciBase is expected to face continued financial pressure. Analysts estimate a mean revenue of 70 million SEK for the current fiscal year, compared to the last actual revenue of 40.46 million SEK. The mean EBIT estimate is -79 million SEK, indicating a significant operating loss. The company's free cash flow is negative at -14.39 million SEK, and capital expenditures are minimal at -127,000 SEK. The risk assessment for SciBase indicates low liquidity and dilution risks. There are no immediate filing-based liquidity or dilution flags. The company's dilution potential is low, and no significant adjustments have been applied to its valuation metrics. The absence of long-term debt and the high cash reserves contribute to the low liquidity risk. Recent events and filings do not indicate any major changes in SciBase's business strategy or financial position. The company's ESG score, particularly the social pillar, is 25.77 out of 100, suggesting room for improvement in social responsibility initiatives. Analysts have provided a uniform price target of 0.50 SEK, indicating a consensus on the stock's valuation.
Key takeaways
  • SciBase Holding AB (publ) has a strong liquidity position with no long-term debt and a current ratio of 3.71.
  • The company is currently unprofitable, with a return on equity of -28.45% and a return on assets of -20.42%.
  • Revenue is concentrated in a single business segment, and there is no geographic diversification data available.
  • Analysts expect continued financial pressure, with a mean EBIT estimate of -79 million SEK for the current fiscal year.
  • The company has low liquidity and dilution risks, with no immediate filing-based flags detected.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencySEK
Revenue$6.6M
Gross profit$4.6M
Operating income-$14.7M
Net income-$15.1M
R&D
SG&A
D&A
SBC
Operating cash flow-$28.4M
CapEx-$127.0k
Free cash flow-$14.4M
Total assets$73.7M
Total liabilities$20.8M
Total equity$52.9M
Cash & equivalents$43.3M
Long-term debt$0.00
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY-4$11.7M-$41.6M-$41.8M-$39.4M
FY-3$17.9M-$46.4M-$43.2M-$39.9M
FY-2$23.2M-$53.9M-$55.6M-$52.6M
FY-1$29.7M-$67.2M-$65.6M-$62.8M
FY0$40.5M-$86.4M-$87.1M-$84.0M
PeriodGross %Op %Net %FCF %
FY-4
FY-3
FY-2
FY-1
FY0
PeriodAssetsEquityCashDebt
FY-4$85.5M$70.8M$65.6M
FY-3$49.9M$25.2M$18.8M
FY-2$64.3M$43.1M$34.1M
FY-1$61.7M$36.6M$11.2M
FY0$52.2M$6.7M$22.6M
PeriodOCFCapExFCFSBC
FY-4-$39.5M-$617.0k-$39.4M
FY-3-$44.5M-$381.0k-$39.9M
FY-2-$52.0M-$383.0k-$52.6M
FY-1-$57.4M-$428.0k-$62.8M
FY0-$84.6M-$228.0k-$84.0M
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ-7$6.6M-$14.7M-$15.1M-$14.4M
FQ-6$8.4M-$14.6M-$17.8M-$16.9M
FQ-5$8.6M-$23.6M-$21.9M-$21.5M
FQ-4$8.9M-$19.6M-$27.5M-$26.8M
FQ-3$8.8M-$22.4M-$26.6M-$25.9M
FQ-2$10.3M-$17.7M-$18.8M-$18.0M
FQ-1$12.5M-$26.7M-$14.1M-$13.1M
FQ0$40.5M
PeriodGross %Op %Net %FCF %
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodAssetsEquityCashDebt
FQ-7$73.7M$52.9M$43.3M
FQ-6$56.1M$37.9M$24.7M
FQ-5$61.7M$36.6M$11.2M
FQ-4$60.1M$43.0M$34.3M
FQ-3$52.9M$32.3M$24.0M
FQ-2$54.0M$33.5M$24.8M
FQ-1$52.2M$6.7M$22.6M
FQ0$58.1M$71.3M
PeriodOCFCapExFCFSBC
FQ-7-$28.4M-$127.0k-$14.4M
FQ-6-$44.8M-$127.0k-$16.9M
FQ-5-$57.4M-$428.0k-$21.5M
FQ-4-$26.0M$0.00-$26.8M
FQ-3-$46.5M-$25.9M
FQ-2-$63.8M-$18.0M
FQ-1-$84.6M-$228.0k-$13.1M
FQ0-$84.6M-$228.0k
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$52.9M
Net cash$43.3M
Current ratio3.7
Debt/Equity0.0
ROA-20.4%
ROE-28.4%
Cash conversion1.9%
CapEx/Revenue-1.9%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskLow
  • No immediate filing-based liquidity or dilution flags were detected.
Industry benchmarks
Activity: Healthcare Equipment · cohort 91 companies
MetricSCIBActivity
Op margin-221.4%-16.5% medp25 -174.5% · p75 8.8%bottom quartile
Net margin-226.6%-16.5% medp25 -172.4% · p75 8.4%bottom quartile
Gross margin69.1%47.4% medp25 34.2% · p75 65.3%top quartile
CapEx / revenue-1.9%-5.4% medp25 -12.5% · p75 -2.2%top quartile
Debt / equity0.0%4.3% medp25 0.0% · p75 28.0%bottom quartile
Observations
IR observations
Mean price target0.50 SEK
Median price target0.50 SEK
High price target0.50 SEK
Low price target0.50 SEK
Mean revenue estimate70,000,000 SEK
Last actual revenue40,461,000 SEK
Mean EBIT estimate-79,000,000 SEK
Social pillar25.77 (0-100)
Governance pillar30.23 (0-100)
ESG controversies score100.00 (0-100, higher = fewer controversies)
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-16 22:14 UTC#c6a3ddb5
Source: analysis-pipeline (hybrid)Generated: 2026-05-29 08:27 UTCJob: 716436f9